We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

Circulating cell free DNA (ccfDNA) fragmentomics for early detection of colorectal carcinoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...

Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...

Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced ...

(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) ...

Glioblastoma (GBM) is an aggressive brain tumor characterized by marked intra- and inter-tumoral heterogeneity and inevitable recurrence. Although extracranial metastasis is rare, circulating tumor ...

The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare ...